Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ZIPRASIDONE HCL MONOHYDRATE

All products: general benefit

Other products in the same Health Canada class (N05A, N05AE) — coverage varies; not interchangeable

  • Lurasidone (Latuda): general benefit, Not a benefit
  • Aripiprazole (Abilify Asimtufii): general benefit
  • Asenapine (Saphris): general benefit
  • Brexpiprazole (Rexulti): general benefit
  • Cariprazine (Vraylar): general benefit
  • Chlorpromazine (Teva-Chlorpromazine): general benefit, Not a benefit

18 more in the class list below

Zeldox · DIN 02298619 · 60mg · capsule

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Zeldox · DIN 02298619 Manufacturer: Upjohn Canada ULC; listing date 2010-07-20 Health Canada: Marketed since 2023-09-15 · brand ZELDOX · ATC N05AE04 ZIPRASIDONE · form Capsule · route Oral · ingredients ZIPRASIDONE (ZIPRASIDONE HYDROCHLORIDE MONOHYDRATE) 60 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $1.5786 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78393 · Verify on the e-Formulary ↗ (DIN 02298619)

Source record
DIN 02298619: Zeldox Raw flags: sec3=Y Item: 281608254; group id 509; item number 1347; lccId None; manufacturer id UJC Source form: Cap; strength: 60mg Recorded listing: General benefit Source prices (unrounded): $2.5658; ministry $1.5786 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02298619 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78393
Interchangeable products
Auro-Ziprasidone · DIN 02449560 · $1.5786
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

LURASIDONE HYDROCHLORIDE

· 38 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4), General benefit (33), Listed, not a benefit (1) · strengths: 20mg, 40mg, 60mg, 80mg, 120mg · Tab

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

FLUPHENAZINE HCL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 1mg, 2mg, 5mg · Tab

HALOPERIDOL

· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab

LOXAPINE SUCCINATE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab

OLANZAPINE

· 116 products · General benefit (99), Off-Formulary Interchangeable, not an ODB benefit (17) · strengths: 5mg, 10mg, 15mg, 20mg, 2.5mg, 7.5mg · Rapid Dissolve Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: schizophrenia and related psychotic disorders
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, PALIPERIDONE ARIPIPRAZOLE · General benefit 1 INDICATIONS ABILIFY (aripiprazole) is indicated for:  the treatment of schizophrenia and related psychotic disorders in adults. PM: https://pdf.hres.ca/dpd_pm/00060025.PDF; date February 11, 2021; DIN 02322374; fetched 2026-09-10 Product monograph  the treatment of schizophrenia and related psychotic disorders in adults. In controlled clinical trials, ABILIFY was found to improve both positive and negative symptoms. ABILIFY has been shown to be more effective than placebo in maintaining clinical improvement for up to 26 weeks in adults. PM: https://pdf.hres.ca/dpd_pm/00060025.PDF; date February 11, 2021; DIN 02322374; fetched 2026-09-10 Product monograph OLANZAPINE · General benefit (99), Off-Formulary Interchangeable, not an ODB benefit (17) Indications ZYPREXA, ZYPREXA ZYDIS (oral olanzapine) is indicated for • the acute and maintenance treatment of schizophrenia and related psychotic disorders. PM: https://pdf.hres.ca/dpd_pm/00085079.PDF; date 2026-06-16; DIN 02229250; fetched 2026-09-10 Product monograph PALIPERIDONE · General benefit 1 INDICATIONS INVEGA® (paliperidone) is indicated for the treatment of schizophrenia and related psychotic disorders. PM: https://pdf.hres.ca/dpd_pm/00059282.PDF; date December 17, 2020; DIN 02300273; fetched 2026-09-10 Product monograph RISPERIDONE · Listed, not a benefit (12), General benefit (70) 1 INDICATIONS Adults Schizophrenia pms-RISPERIDONE (risperidone) is indicated for the acute treatment and maintenance treatment of schizophrenia and related psychotic disorders. PM: https://pdf.hres.ca/dpd_pm/00062538.PDF; date August 13, 2021; DIN 02252007; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS  Schizophrenia ZELDOX (ziprasidone) is indicated for the treatment of schizophrenia and related psychotic disorders. The prescriber should consider the finding of ziprasidone’s greater capacity to prolong the QT/QTc interval compared to other antipsychotic drugs (see 2 CONTRAINDICATIONS, 7 WARNINGS AND PRECAUTIONS). The efficacy of ziprasidone was established in short-term (4- and 6-week) controlled trials of schizophrenic inpatients (see 14 CLINICAL TRIALS). ZELDOX has been shown to be effective in maintaining clinical improvement during long- term therapy (1-year). The health professional who elects to use ZELDOX for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.  Bipolar Disorder ZELDOX is indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder. The prescriber should consider the finding of ziprasidone’s greater capacity to prolong the QT/QTc interval compared to other antipsychotic drugs (see 2 CONTRAINDICATIONS, 7 WARNINGS AND PRECAUTIONS). The efficacy of … https://pdf.hres.ca/dpd_pm/00072509.PDF PM date: SEP 15, 2023 Source product: ZELDOX; DIN 02298597; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.